TSXV:MNX

Stock Analysis Report

Executive Summary

Manitex Capital Inc. does not have significant business.


Snowflake Analysis

Adequate balance sheet and slightly overvalued.

Share Price & News

How has Manitex Capital's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MNX has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

MNX

0.5%

CA Healthcare

2.1%

CA Market


1 Year Return

n/a

MNX

-42.6%

CA Healthcare

-21.2%

CA Market

Return vs Industry: MNX exceeded the Canadian Healthcare industry which returned -46.7% over the past year.

Return vs Market: MNX exceeded the Canadian Market which returned -24.8% over the past year.


Shareholder returns

MNXIndustryMarket
7 Day0%0.5%2.1%
30 Day-6.4%-20.8%-13.8%
90 Dayn/a-25.6%-21.9%
1 Yearn/a-40.9%-42.6%-18.6%-21.2%
3 Year-58.5%-58.5%-50.7%-56.8%-11.0%-19.3%
5 Year-37.1%-37.1%-23.5%-40.8%1.6%-13.6%

Price Volatility Vs. Market

How volatile is Manitex Capital's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Manitex Capital undervalued compared to its fair value and its price relative to the market?

0.17x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MNX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MNX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MNX is good value based on its PE Ratio (10.3x) compared to the Healthcare industry average (17.4x).

PE vs Market: MNX is poor value based on its PE Ratio (10.3x) compared to the Canadian market (10.3x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MNX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MNX is good value based on its PB Ratio (0.2x) compared to the CA Healthcare industry average (1.9x).


Next Steps

Future Growth

How is Manitex Capital forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

33.3%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Manitex Capital has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Manitex Capital performed over the past 5 years?

-8.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MNX has a large one-off loss of CA$436.3K impacting its October 31 2019 financial results.

Growing Profit Margin: MNX's current net profit margins (6.1%) are lower than last year (43.1%).


Past Earnings Growth Analysis

Earnings Trend: MNX's earnings have declined by -23.6% per year over the past 5 years.

Accelerating Growth: MNX's earnings growth over the past year (128.8%) exceeds its 5-year average (-23.6% per year).

Earnings vs Industry: MNX earnings growth over the past year (128.8%) exceeded the Healthcare industry 11.4%.


Return on Equity

High ROE: MNX's Return on Equity (-7.2%) is considered low.


Next Steps

Financial Health

How is Manitex Capital's financial position?


Financial Position Analysis

Short Term Liabilities: MNX's short term assets (CA$3.8M) exceed its short term liabilities (CA$899.7K).

Long Term Liabilities: MNX's short term assets (CA$3.8M) exceed its long term liabilities (CA$541.7K).


Debt to Equity History and Analysis

Debt Level: MNX's debt to equity ratio (3.2%) is considered satisfactory.

Reducing Debt: MNX's debt to equity ratio has reduced from 6.2% to 3.2% over the past 5 years.

Debt Coverage: MNX's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if MNX's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is Manitex Capital's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MNX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MNX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MNX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MNX's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

19.3yrs

Average board tenure


CEO

Steve Saviuk (60yo)

no data

Tenure

CA$344,068

Compensation

Mr. Steven Saviuk, also known as Steve, CA, has been Executive Chairman of the Board of Directors at Ortho Regenerative Technologies Inc. since March 06, 2019. He serves as the Chairman and Chief Executive ...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD243.45K) is above average for companies of similar size in the Canadian market ($USD158.76K).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Steven Saviuk
Chairmanno dataCA$344.07k8.34% CA$230.6k
Helen Saviuk
CFO & Director10.08yrsCA$167.50k3.47% CA$95.8k
Ronald Perry
Secretary & Independent Director19.33yrsno data0.17% CA$4.6k
Wynn Rimstad
Independent Director19.33yrsCA$1.00kno data

19.3yrs

Average Tenure

Experienced Board: MNX's board of directors are seasoned and experienced ( 19.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Manitex Capital Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Manitex Capital Inc.
  • Ticker: MNX
  • Exchange: TSXV
  • Founded:
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: CA$2.763m
  • Shares outstanding: 12.56m
  • Website: https://www.manitexcapital.com

Location

  • Manitex Capital Inc.
  • 16667 Hymus Boulevard
  • Kirkland
  • Quebec
  • H9H 4R9
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MNXTSXV (TSX Venture Exchange)YesCommon SharesCACADOct 2000

Biography

Manitex Capital Inc. does not have significant business. It focuses on acquiring interests in life sciences, cleantech, and sustainable products/technologies companies. Previously, it was engaged in the acquisition and markets specialty pharmaceutical products, and distributes third-party pharmaceutical products, as well as holds a portfolio in marketable securities. The company is headquartered in Kirkland, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/08 03:17
End of Day Share Price2020/03/30 00:00
Earnings2020/01/31
Annual Earnings2019/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.